Better Health for All

Apyx Medical's core products, Renuvion, J-Plasma, and AYON, are advanced energy technologies used in cosmetic and surgical markets for tissue contraction, fat removal, and body contouring.

These products are supported by over 90 clinical documents and have received multiple FDA clearances for specific indications, including post-liposuction use, neck and submental lax skin, and moderate to severe wrinkles. These on-label uses provide substantial health benefits. However, the FDA issued warnings in March 2022 against off-label use for dermal resurfacing due to reports of serious adverse events such as second- and third-degree burns, infection, nerve damage, and significant bleeding, some requiring intensive care. Apyx's labeling specifically warns against dermal resurfacing. The company submitted 90 medical device reports (MDRs) related to subdermal coagulation since 2017, representing approximately 0.06% of over 150,000 procedures performed globally. MDRs increased from 15 in 2020 to 32 in 2021, while procedures more than doubled. A Class 2 recall was initiated in April 2020 for 13,948 units of a Renuvion/J-Plasma handpiece due to potential stress fractures, which was terminated in September 2022. Apyx is actively engaged with the FDA to obtain 510(k) clearances for on-label indications, having submitted multiple premarket notifications, including for the AYON Body Contouring System ahead of schedule. The company is dedicated to educating and extensively training its surgeon customers, and clearances will allow for training of new users and communication of recommended parameters.

Fair Money & Economic Opportunity

Apyx Medical Corporation is an advanced energy technology company that designs, develops, and markets products in the cosmetic and surgical markets, such as Renuvion Cosmetic Technology, generators, and handpieces.

The company's core business, as evidenced by its product offerings and revenue streams (e.g., Surgical Aesthetics Revenue, OEM Revenue), does not involve lending, insuring, moving, or storing money for consumers. Therefore, all KPIs related to fair money and economic opportunity, which are designed for financial institutions, are not applicable to Apyx Medical Corporation, aligning with the '0' tier for 'Not applicable' in the rubric.

Fair Pay & Worker Respect

Employee engagement is very low, with an average Glassdoor rating of 2.2 out of 5 stars and only 23% of employees recommending working there.

This rating is 37% below the manufacturing industry average of 3.5 stars. Voluntary employee turnover is high, particularly in the Regulatory department, with reviews citing issues like workload distribution, favoritism, and ineffective HR support. Conversely, the company offers comprehensive health insurance coverage for full-time employees and eligible dependents at minimal cost, including pharmacy, HSA/FSA options, vision care, and employer-paid short-term disability.

Fair Trade & Ethical Sourcing

Apyx Medical Corporation published its first ESG data via a tear sheet on July 27, 2022, covering the year ended December 31, 2021.

This reporting follows Sustainability Accounting Standards Board (SASB) standards for the Medical Equipment and Supplies sector and focuses on supply chain management and supplier business ethics. However, the provided article does not contain specific quantitative data for any of the ethical sourcing KPIs, such as fair-trade certification share, audit frequency, forced or child labor incidents, traceability coverage, remediation speed, ethical clause coverage, materials risk index, or supplier diversity spend.

Honest & Fair Business

Apyx Medical Corporation announced on March 16, 2020, that it would restate its previously issued consolidated financial statements for the twelve months ended December 31, 2018, the quarterly statements for the three and nine months ended September 30, 2018, and the three months ended March 31, 2019.

These restatements were due to errors including the elimination of markup on intercompany sales, collection and remission of employee income and payroll taxes, accounting for stock-based compensation expense, and accounting for revenue and deferred expenses related to OEM contracts. The company also identified material weaknesses in internal controls over financial reporting in 2018. The board has five independent members who meet NASDAQ Stock Market LLC independence requirements. The company states it has policies and procedures in place to ensure compliance with the FCPA, OFAC restrictions, and other anti-corruption laws, but explicitly provides no assurance that these policies will prevent violations. The company mentions ISO 13485 certification and FDA registration for its manufacturing facilities, and external audit opinions.

Kind to Animals

Apyx Medical Corporation is listed as a company that uses animal testing.

The company released its first ESG data tear sheet for the year ended December 31, 2021, which outlines general ESG priorities but does not provide specific details on animal welfare or alternative testing practices.

No War, No Weapons

Apyx Medical Corporation's core business is in cosmetic and surgical markets, with products like Renuvion Cosmetic Technology and surgical generators. The company's ESG reports do not indicate any involvement in arms manufacturing, military contracts, or dual-use technologies with military applications.

There is no evidence of sales to embargoed regimes, lobbying related to arms control, or engagement in intelligence or surveillance activities. The company does not have defense assets to divest, nor does it have conflict-linked partners or operations in conflict-affected areas requiring human rights due diligence. However, in 2019, Apyx was unable to determine if conflict minerals used in its products originated in Covered Countries (DRC and surrounding regions), and suppliers could not determine with certainty if these minerals were DRC Conflict Free. Substantially all products were classified as 'DRC Conflict Undeterminable' in 2019.

Planet-Friendly Business

Apyx Medical Corporation's sole public ESG disclosure is its 2021 ESG Tear Sheet, released in July 2022, which covers data for the year ended December 31, 2021.

As of November 2025, this disclosure is four years out of date. For nearly all specific environmental performance indicators, the available articles explicitly state that no information is provided or publicly disclosed post-2021. While a Life Cycle Assessment (LCA) was underway in 2021 to evaluate packaging impact, and a packaging reduction strategy was indicated, no specific 2025 targets or quantifiable results have been released for either. No specific regulatory actions, violations, fines, or compliance issues are mentioned in the available reports.

Respect for Cultures & Communities

No specific, concrete data points or actions related to the 'Respect for Cultures & Communities' value were found in the provided articles for Apyx Medical Corporation.

While the company released its first ESG data tear sheet for the year ended December 31, 2021, in accordance with SASB standards and UN SDGs, the articles do not disclose any details from this report or other evidence relevant to the specified KPIs.

Safe & Smart Tech

Apyx Medical Corporation states that it has been in material compliance with all applicable state, federal, and international data privacy, security, and breach notification laws and regulations, including HIPAA, CCPA, and GDPR, for the last three years.

The company's privacy policy, last updated on January 7, 2020, outlines standard data collection and retention practices, including Personally Identifiable Information and Non-Personally Identifiable Information. It provides users with the ability to review, update, and correct their information and unsubscribe from email newsletters, with European users having additional rights under GDPR, which indicates good user privacy controls. The company received FDA 510(k) clearances for its Renuvion product in 2012, May 2022, and July 2022, but also received an FDA Medical Device Safety Communication in March 2022, which requested revisions to messaging, labeling, and training materials.

Zero Waste & Sustainable Products

The company lacks a publicly announced, active take-back or recycling program for its used single-use handpieces.

Hazardous waste at its U.S. and Bulgaria facilities is safely disposed of by an accredited third-party. The company has not provided updated, quantifiable waste reduction goals since its 2021 ESG Tear Sheet, which is four years out of date as of November 2025.